About: Benjamin Wolozin     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : owl:Thing, within Data Space : dbpedia.org associated with source document(s)
QRcode icon
http://dbpedia.org/describe/?url=http%3A%2F%2Fdbpedia.org%2Fresource%2FBenjamin_Wolozin

Benjamin Wolozin is an American pharmacologist and neurologist currently at Boston University School of Medicine and an Elected Fellow of the American Association for the Advancement of Science. Benjamin Wolozin, M.D., Ph.D. received his B.A. from Wesleyan University (Middletown, CT) and his M.D., Ph.D. from the Albert Einstein College of Medicine. He is currently a professor of Pharmacology, Neurology and the Program in Neuroscience at Boston University School of Medicine. He is also co-founder and Chief Scientific Officer (CSO) of Aquinnah Pharmaceuticals Inc., a biotechnology company developing novel therapeutics to treat Alzheimer's disease and Amyotrophic Lateral Sclerosis.

AttributesValues
rdf:type
rdfs:label
  • Benjamin Wolozin (en)
rdfs:comment
  • Benjamin Wolozin is an American pharmacologist and neurologist currently at Boston University School of Medicine and an Elected Fellow of the American Association for the Advancement of Science. Benjamin Wolozin, M.D., Ph.D. received his B.A. from Wesleyan University (Middletown, CT) and his M.D., Ph.D. from the Albert Einstein College of Medicine. He is currently a professor of Pharmacology, Neurology and the Program in Neuroscience at Boston University School of Medicine. He is also co-founder and Chief Scientific Officer (CSO) of Aquinnah Pharmaceuticals Inc., a biotechnology company developing novel therapeutics to treat Alzheimer's disease and Amyotrophic Lateral Sclerosis. (en)
dcterms:subject
Wikipage page ID
Wikipage revision ID
Link from a Wikipage to another Wikipage
sameAs
dbp:wikiPageUsesTemplate
has abstract
  • Benjamin Wolozin is an American pharmacologist and neurologist currently at Boston University School of Medicine and an Elected Fellow of the American Association for the Advancement of Science. Benjamin Wolozin, M.D., Ph.D. received his B.A. from Wesleyan University (Middletown, CT) and his M.D., Ph.D. from the Albert Einstein College of Medicine. He is currently a professor of Pharmacology, Neurology and the Program in Neuroscience at Boston University School of Medicine. He is also co-founder and Chief Scientific Officer (CSO) of Aquinnah Pharmaceuticals Inc., a biotechnology company developing novel therapeutics to treat Alzheimer's disease and Amyotrophic Lateral Sclerosis. Dr. Wolozin has published over 150 papers, including publications in Science, Nature and PNAS. He has received numerous awards through his career including election as a fellow of the AAAS, the Spivack Distinguished Scholar in Neuroscience Award (BU), the Zenith Award (Alzheimer Association), Collaborator of the Year (BU Evans Center), Fellow of the Society for Skeptical Inquiry, Teacher of the year (Loyola University), A.E. Bennett Award (Soc. For Biological Psychiatry), Commissioned Officer Commendation Award (PHS), Donald B. Linsdley Award (Soc. For Neuroscience), Medical Scientist Training Fellowship, NSF Fellowship (declined), Hawk Prize for Biochemical Research (Wesleyan), Departmental Honors and Magna Cum Laude Latin honors (Wesleyan University). Dr. Wolozin has extensive research experience in the field of neurodegenerative disease. His research investigates the pathophysiology of several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. His research examines molecular and cellular aspects of disease, and utilizes a variety of transgenic models including mice, C. elegans, primary neurons and cell lines. Dr. Wolozin is also experienced in the study of human brain samples or cell lines from patients. His specific research interests emphasize the role of protein aggregation in neurodegenerative disease as well as metabolic consequences of stress linked to protein aggregation or cellular damage. Dr. Wolozin's contributions to understanding of neurodegenerative disease cover a wide range of subjects. In 1986 he identified the antibody Alz-50, which was one of the first antibodies to identify the conformation specific epitopes of microtubule associated protein tau that are abundant in the brains of patients with Alzheimer's disease. In 2000 he was the first scientist to show that individuals taking statins (a form of cholesterol lowering medication) exhibit much lower rates of Alzheimer's disease. (en)
prov:wasDerivedFrom
page length (characters) of wiki page
foaf:isPrimaryTopicOf
is Link from a Wikipage to another Wikipage of
is Wikipage redirect of
is foaf:primaryTopic of
Faceted Search & Find service v1.17_git139 as of Feb 29 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 08.03.3330 as of Mar 19 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (378 GB total memory, 67 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software